Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

69 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.Endocrine · 2024
   Pooled it
2. Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis.JAMA network open · 2022
   Pooled it
3. Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.Primary care diabetes · 2022
   Pooled it
4. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.Journal of endocrinological investigation · 2021
   Trial
5. COVID-19: Diabetes Perspective-Pathophysiology and Management.Pathogens (Basel, Switzerland) · 2023
   Review
6. Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.European heart journal. Cardiovascular pharmacotherapy · 2022
   Article
7. Perceptions about the Management of Patients with DM2 and COVID-19 in the Hospital Care Setting.Journal of clinical medicine · 2022
   Article
8. Knowledge, Attitudes, and Practices of COVID-19 Safety Measures Among Type 1 Diabetes Mellitus Patients at King Abdulaziz University Hospital: A Cross-Sectional Study.Cureus · 2022
   Article
9. The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course-A Narrative Review.Frontiers in clinical diabetes and healthcare · 2022
   Review
10. COVID-19 and diabetes-Two giants colliding: From pathophysiology to management.Frontiers in endocrinology · 2022
    Review
11. Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking.Network modeling and analysis in health informatics and bioinformatics · 2022
    Article
12. Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review.Journal of diabetes and metabolic disorders · 2021
    Review
13. Biologia Futura: is ADAM 17 the reason for COVID-19 susceptibility in hyperglycemic and diabetic patients?Biologia futura · 2021
    Review
14. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.European geriatric medicine · 2021
    Review
15. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.International journal of molecular sciences · 2021
    Review
16. Pharmacological management of COVID-19 in type 2 diabetes.Journal of diabetes and its complications · 2021
    Review
17. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.Diabetes & metabolism · 2021
    Review
18. Awareness regarding COVID-19 and problems being faced by young adults with type 1 diabetes mellitus amid nationwide lockdown in India: A qualitative interview study.Primary care diabetes · 2021
    Article
19. Interferon-inducer antivirals: Potential candidates to combat COVID-19.International immunopharmacology · 2021
    Review
20. Caring for patients with diabetes during COVID-19 pandemic: Important considerations for pharmacists.Research in social & administrative pharmacy : RSAP · 2021
    Article

9 more citing papers are in PubMed but not listed here.

Corrections and comments

• Commented on by
  COVID-19 and diabetes: Is metformin a friend or foe?2020
• Commented on by
  Comment on "Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?"2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as